JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Home・Akciju saraksts・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Slēgts

SektorsVeselības aprūpe

148.41 -0.42

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

145.87

Max

150.43

Galvenie mērījumi
By Trading Economics
Ienākumi	240M 26M
Pārdošana	-18M 984M
P/E Sektora vidējais	592.3 34.393
Peļņas marža	2.629
Darbinieki	18,700
EBITDA	271M 184M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+14.77% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	371M 8.2B
Iepriekšējā atvēršanas cena	148.83
Iepriekšējā slēgšanas cena	148.41

Ziņu noskaņojums

By Acuity

48%

52%

156 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

117.16 / 144.77 Atbalsts un pretestība

Charles River Laboratories International Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 11. aug. 17:49 UTC

Galvenie tirgus virzītāji

180 Life Sciences Stock Jumps on $156 Million Notes Sale

2025. g. 11. aug. 17:18 UTC

Galvenie tirgus virzītāji

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

2025. g. 11. aug. 16:25 UTC

Peļņas

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

2025. g. 11. aug. 23:50 UTC

Tirgus saruna

Nikkei May Rise as Yen Weakens -- Market Talk

2025. g. 11. aug. 23:42 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2025. g. 11. aug. 23:42 UTC

Tirgus saruna

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

2025. g. 11. aug. 23:36 UTC

Tirgus saruna

Gold Edges Higher on Likely Technical Recovery -- Market Talk

2025. g. 11. aug. 23:32 UTC

Tirgus saruna

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

2025. g. 11. aug. 23:02 UTC

Tirgus saruna

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

2025. g. 11. aug. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 11. aug. 20:37 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

2025. g. 11. aug. 20:37 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Bakkt Holdings 2Q Rev $577.9M >BKKT

2025. g. 11. aug. 20:37 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

2025. g. 11. aug. 20:22 UTC

Peļņas

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

2025. g. 11. aug. 20:22 UTC

Peļņas

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

2025. g. 11. aug. 20:22 UTC

Peļņas

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

2025. g. 11. aug. 20:22 UTC

Peļņas

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

2025. g. 11. aug. 20:22 UTC

Peļņas

Exodus Movement 2Q Rev $25.8M >EXOD

2025. g. 11. aug. 20:14 UTC

Tirgus saruna

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

2025. g. 11. aug. 19:12 UTC

Tirgus saruna

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

2025. g. 11. aug. 18:56 UTC

Tirgus saruna

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

2025. g. 11. aug. 18:31 UTC

Tirgus saruna

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

2025. g. 11. aug. 17:43 UTC

Tirgus saruna

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

2025. g. 11. aug. 17:28 UTC

Tirgus saruna

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

2025. g. 11. aug. 17:16 UTC

Tirgus saruna

Commodity Longs Fall to 11-Month Low -- Market Talk

2025. g. 11. aug. 16:42 UTC

Iegādes, apvienošanās, pārņemšana

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

2025. g. 11. aug. 16:27 UTC

Iegādes, apvienošanās, pārņemšana

BBVA Says Sabadell Offer Remains in Effect

2025. g. 11. aug. 16:26 UTC

Iegādes, apvienošanās, pārņemšana

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

2025. g. 11. aug. 16:25 UTC

Iegādes, apvienošanās, pārņemšana

Banco de Sabadell Announced TSB Sale on July 1

2025. g. 11. aug. 16:25 UTC

Iegādes, apvienošanās, pārņemšana

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Salīdzinājums

Cenas izmaiņa

Charles River Laboratories International Inc Prognoze

Cenas mērķis

By TipRanks

14.77% augšup

Prognoze 12 mēnešiem

Vidējais 170.92 USD 14.77%

Augstākais 190 USD

Zemākais 151 USD

Pamatojoties uz 14 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

14 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 14 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

117.16 / 144.77Atbalsts un pretestība

Recent bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

156 / 374 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.